Aspire Biopharma Provides Q3 2025 Business Update

About this update from Aspire Biopharma Holdings, Inc.

[{"type":"text","content":"ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provides a business update for the quarter ended September 30, 2025.","length":291,"tagName":"p"},{"type":"text","content":"Q3 2025 and Recent Highlights","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded its scientific team with the addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. Dr. Jaroszeski, who holds a PhD in Engineering Science with a dissertation focused on mechanically facilitated cell-cell electrofusion. His expertise is expected to assist in further developing Aspire's unique sublingual delivery technology.","length":417,"tagName":"p"}]},{"val":[{"type":"text","content":"Submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company's lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval. On November 13, 2025, the FDA responded positively to the request and stated it would provide written responses in lieu of a meeting no later than January 2, 2026.","length":535,"tagName":"p"}]},{"val":[{"type":"text","content":"Participated in the CPHI Frankfurt trade show, the world's largest pharmaceutical event. The Company engaged in numerous strategic discussions with global pharmaceutical companies regarding technical collaboration and licensing opportunities for its lead product candidate, a novel sublingual high-dose aspirin. The conference has led to several licensing opportunities that the Company is considering.","length":406,"tagName":"p"}]},{"val":[{"type":"text","content":"Filed an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application - which seeks patent protection of Aspire's proprietary technology in a variety of classes of drugs and other substances--focuses exclusively on protecting the Company's advanced sublingual drug delivery syst...

More updates from Aspire Biopharma Holdings, Inc.